杜避炎安全無害？研究顯示，杜避炎會增加異位性皮膚炎患者得皮膚 T 細胞淋巴癌的風險

作者：黃于家

本篇研究，"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study"，請見這裡，期刊摘要如下：

Background：

Dupilumab, a human monoclonal antibody targeting the interleukin 4 alpha receptor, is used for treatment of moderate to severe atopic dermatitis (AD). 

Previous studies have reported diagnoses of cutaneous T cell lymphoma (CTCL) after dupilumab use.

Objectives：

Investigate the risk of CTCL after dupilumab use in patients with AD.

Methods：

Using the TrinetX database, incidence of cutaneous and lymphoid malignancies including CTCL was compared between a cohort of patients with AD who used dupilumab and a cohort of patients with AD who never used dupilumab. 

A second analysis excluding prior disease-modifying antirheumatic drug use was performed. Propensity score matching was performed to control for covariates.

Results：

An increased risk of CTCL was found in the cohort of AD patients who used dupilumab (odds ratio 4.1003, 95% confidence interval 2.055-8.192). The increased risk persisted after exclusion of prior disease-modifying antirheumatic drug use. 

Risk was not increased for other cutaneous or lymphoid malignancies. Most (27/41) cases of CTCL were diagnosed more than 1 year after dupilumab use.

Limitations：

There is potential for misclassification in the database. Severity of AD could not be assessed. Association between dupilumab and CTCL does not prove causality.

Conclusions：

Dupilumab use is associated with an increased risk of CTCL in patients with AD in this cohort.

杜避炎治療後的中醫經方治療實例，請見這裡。

異位性皮膚炎，中醫經方的治療實例，請見這裡。

小兒異位性皮膚炎，中醫經方的治療實例，請見這裡。

成人異位性皮膚炎，中醫經方的治療實例，請見這裡。

異位性皮膚炎，期刊研究，請看這裡。

期刊研究整理，請見這裡。

黃于家醫師的門診資訊